Avalo Therapeutics announced a 1-for-240 reverse stock split of the Company’s common stock, par value 1c, which will be effective at 5:00 pm Eastern Time on December 28. The Company’s common stock will trade on the Nasdaq Capital Market on a split-adjusted basis beginning on December 29 under the Company’s existing trading symbol “AVTX“. The Company is implementing the reverse stock split as planned to increase the per share price of its common stock to regain compliance with the listing requirements of the Nasdaq Capital Market. The new CUSIP number following the reverse stock split will be 05338F306.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AVTX:
- Avalo Encourages Stockholders to Vote FOR the Reverse Stock Split
- Avalo Therapeutics encourages stockholders for FOR reverse stock split
- Avalo Therapeutics reports Q3 EPS (11c) vs 34c last year
- Avalo Reports Third Quarter 2023 Financial Results and Provides Business Updates
- Avalo Therapeutics completes divestiture of AVTX-800 series
